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lafaxine or sustained release venlafaxine. The results of
this study lend insight useful in making prescribing/for-
mulary decisions for patients with newly diagnosed de-
pression.
PMH3
IS DEPRESSION THE MAJOR CAUSE OF 
IMPAIRED QUALITY OF LIFE IN 
SCHIZOPHRENIC PATIENTS?
Toumi M1, Pettersson Å1, Llorca PM2, Lançon C3, Aballéa S1
1Lundbeck SA, Paris, France; 2CHU Sainte-Marie, Clermont-
Ferrand, France; 3CHU Sainte Marguerite, Marseilles, France
OBJECTIVES: Schizophrenia is a complex and invalidat-
ing disease with a wide range of symptoms and often so-
cial exclusion. Patients’ quality of life is heavily impaired.
The associations between the different symptoms and the
QoL, as well as the possible impact of the patient man-
agement are still not well known. Our objective was to
study the associations between health status, quality of
life, general functioning and patient management in
schizophrenic patients. METHODS: 238 schizophrenic
patients were assessed in a cross sectional study with the
Lehman QoL scale, EuroQoL, SF-36, Calgary Depression
Scale, CGI, GAF and PANSS. At the same time the pa-
tient management was assessed. A progressive approach
using graphical chain models was adopted to determine
the strength of the associations between the different
variables. RESULTS: Depression was strongly associated
with the subjective dimensions of QoL, the utility of Eu-
roQoL and with the mental health sub-score of SF-36.
The schizophrenic symptoms (PANSS) seem to have no
direct impact on the QoL, but only through their associa-
tion to depression and impaired functioning (GAF).
Other factors that seem to have and impact on the QoL
are recent hospitalisation and the type of antipsychotic
drug prescribed, atypical antipsychotics seem more favour-
able compared to typical. CONCLUSIONS: Depression
seems to be the major factor impairing the quality of life
of schizophrenic patients.
PMH4
ASSESSMENT OF PATIENTS’ ATTITUDES 
TOWARD ANTIPSYCHOTIC TREATMENT IN A 
40-WEEK RANDOMIZED, CONTROLLED TRIAL
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OBJECTIVES: Pharmacotherapy can reduce or prevent
symptom relapse among schizophrenics, thereby provid-
ing long-term benefits. Relapse is common following
noncompliance or discontinuation of antipsychotic medi-
cation, and dissatisfaction with medication may lead to
noncompliance resulting in symptom relapse and in-
creased health care expenditures. We assessed how
schizophrenic patients view the use of antipsychotics.
METHODS: The Drug Attitude Inventory (DAI), com-
prised of 10 “yes/no” questions about efficacy, side ef-
fects and satisfaction, was used to characterize patients’
attitudes and subjective responses to antipsychotic treat-
ment. The DAI was administered to subjects with chronic
or subchronic schizophrenia or schizoaffective disorder in
a forty-week, double-blind, randomized, parallel-group,
flexible-dose study of two regimens of ziprasidone (80 to
120 mg QD or 40 to 80 BID) and one regimen of halo-
peridol (5 to 20 mg daily). A score was calculated as the
sum of the responses to all questionnaire items, and the
subsets of six subjective and four attitudinal questions. A
categorical linear model was used to analyze the marginal
probabilities of favorable responses to the questions. RE-
SULTS: For total, subjective and attitudinal items, DAI
scores at baseline were comparable between treatment
groups. Overall item response significantly favored ziprasi-
done at week 40 (p  0.0016; 7/10 questions showed a
higher percentage of positive responses for ziprasidone,
and the magnitude of differences per question ranged
from 14.2% to 3.7%). This difference was primarily
due to positive responses to the subjective questions (p 
0.0006; 4/6 questions showed a higher percentage of pos-
itive responses for ziprasidone, and the magnitude of dif-
ferences per question ranged from 14.2% to 3.2%).
CONCLUSIONS: Patients in the ziprasidone groups had
a significantly more positive attitude regarding their med-
ication than those in the haloperidol group over 40 weeks
of treatment. These findings have implications for greater
patient compliance with ziprasidone treatment, which
may lead to decreases in relapse rates, hospitalizations,
and other health care resource use.
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OBJECTIVE: Examine which participant level factors
impact the time to switch from first- to second-genera-
tion agents among participants in the Schizophrenia Care
and Assessment Project (SCAP). METHODS: Baseline
data identified participants not receiving second genera-
tion agents (n  520). Accelerated failure time (AFT)
modeling (Weibull distribution error) applied. Number
of years between disease onset and study initiation in-
cluded. Dependent variable: days between study initia-
tion and first switch to second-generation. Right censor-
ing addressed through dichotomous censor variable (1 
switch during window). RESULTS: About one-fourth
(n  133) experienced switch (mean time to switch 
171.08 days). Working hypothesis: persons with higher
side effect and symptom scores and lower functioning
would exhibit shorter time to switch. Persons with higher
side effect scores (AIMS) experienced longer interval until
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switch (1.08; p  0.01) and those with higher depression
scores (MADRS) experienced shorter time to switch
(0.97; p  0.02). Those receiving service through univer-
sity hospital experienced longer interval (3.19; p  0.01).
The computed hazard rate (0.68) indicates the risk of
switch is decreasing over time. CONCLUSIONS: Find-
ings indicate that symptoms and type of service delivery
site are significant in determining the switch from older
to newer agents. The shorter interval for those with
higher depression scores is expected and is probably re-
flective of clinical intervention aimed toward the amelio-
ration of negative symptoms. Interestingly, the longer
interval for those with higher side effect scores was con-
trary to expectation and may indicate that the motivating
influence to change is more related to the presentation of
primary disease state, rather than the reduction of sec-
ondary symptoms associated with the first generation
medications. The longer interval for those receiving care
in a university hospital setting is perplexing since it is
usually expected that medication adjustment will occur
during hospital stays. Further investigation of this phe-
nomenon may be aided by the inclusion of physician level
information, which is anticipated in upcoming analyses.
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OBJECTIVES: While most current antidepressant agents,
such as SSRIs and dual action agents are reasonably ef-
fective in ameliorating depressive symptomatology in
older patients, less is known about their impact on con-
current instrumental activities of daily living (IADL’s).
This study examines change in IADL’s, such as the capac-
ity to use the telephone, travel, shop, cook, do house-
work, handle money, or take medicine, from admission
to three-month post-discharge follow-up in geropsychiat-
ric patients (age 55 and older) with major depression
(ICD-9-CM codes 296.20-296.36) treated with fluoxe-
tine (n  77), mirtazapine (n  36), sertraline (n  145),
or venlaxafine (n  56). METHODS: Data were ob-
tained from the CQISM Outcomes Measurement Sys-
tem, which tracked patients admitted to geropsychiatric
inpatient programs in 111 general hospitals across 33
states between 1997–1999. IADL’s were measured by se-
lected items from the Duke OARS Multidimensional
Functional Assessment Questionnaire (Lawton & Brody,
1969). A Medication Usage Questionnaire was used to
track medications prescribed. One-way Analyses of Vari-
ance and if significant, Tukey’s pairwise comparisons
were used to compare medication groups. RESULTS: At
admission, patients exhibited moderate to severe inability
to independently carry out IADL’s (Mean score of 14 to
15 out of 21). Medication groups were indistinguishable
on change scores in overall IADL’s from time of admis-
sion to follow-up. On average, patients showed no
change in their ability to carry out IADL’s during this
time period, despite an improvement in level of depres-
sion, as measured by the collateral version of the Geriat-
ric Depression Scale (Nitcher, Burke, Roccaforte, &
Wengel, 1993). CONCLUSIONS: Antidepressant agents
in this analysis were associated with modest improve-
ment in IADL’s as assessed by the Duke OARS Multi-
demsional Functional Assessment in Older Adults. New
treatment modalities that improve IADL’s along with de-
pressive symptomatology in older patients would be ben-
eficial. Further controlled studies are needed to better un-
derstand these findings.
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OBJECTIVES: Numerous antidepressant agents are
available to treat geropsychiatric patients with depres-
sion. While most current agents are reasonably effective
in ameliorating depressive symptomatology, less is known
about the impact of these agents on concurrent maladap-
tive behaviors. This study examines change in sixteen
such behaviors from admission to discharge to three-
month post-discharge follow-up in geropsychiatric pa-
tients (age 55 and older) with major depression (ICD-9-
CM codes 296.20-296.36) treated with fluoxetine (n 
292), mirtazapine (n  288), sertraline (n  744), or ven-
laxafine (n  289). METHODS: Data were obtained
from the CQISM Outcomes Measurement System,
which tracked patients admitted to geropsychiatric inpa-
tient programs in 111 general hospitals across 33 states
between 1997–1999. Maladaptive behaviors were mea-
sured by the Psychogeriatric Dependency Rating Scale
(PGDRS) (Wilkinson & Graham-White, 1980) and a
Medication Usage Questionnaire was used to track medi-
cations prescribed at admission, discharge, and follow-
up. One-way Analyses of Variance and if significant,
Tukey’s pairwise comparisons were used to compare
medication groups. RESULTS: At admission, patients ex-
hibited mild to moderate evidence of maladaptive behav-
iors (Mean PGDRS overall score of 20 out of 48). Medi-
cation groups were indistinguishable on change scores in
overall maladaptive behaviors from time of admission to
discharge (average length of stay around 16 days), dis-
charge to follow-up, or admission to follow-up. On aver-
age, patients showed a very modest improvement (1–2
points) on the PGDRS from admission to discharge,
modest decline from discharge to follow-up (0–2 points),
